Prescription medicine
Iomeprol Brand names: Iomervu
Iomeprol (Iomervu) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.
- No generic listed
- Boxed warning
Check it at the source: the iomeprol FDA label on DailyMed (effective February 5, 2026, BRACCO DIAGNOSTICS INC); the NDA 216016 record on Drugs@FDA; every iomeprol label on DailyMed.
Highlights of the record
FDA label of February 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION.
Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only [see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. IOMERVU is for intra-arterial or intravenous use only.
Used for
From the label: indications and usageIOMERVU is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac ch
Forms and strengths
- 714 mg/ml
- 816 mg/ml
Injection (solution).
On the market
- Earliest approval on file
- November 27, 2024 Iomervu, Bracco; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,328 through July 30, 2026
What is iomeprol used for?
From the label: indications and usageIOMERVU is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients Intravenous Procedures † ( 1.2 ) Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT angiography in adults and pediatric patients CT urography in adults and pediatric patients † Specific concentrations are recommended for each type of imaging procedure. […]
FDA pharmacologic class: Radiographic Contrast Agent.
Source: FDA drug label (IOMERVU), BRACCO DIAGNOSTICS INC, effective February 5, 2026 (SPL set cb2e0e00-7c93-0fb4-89a5-861641662a5a), via openFDA; the full label on DailyMed
Is there a generic for iomeprol (Iomervu)?
No generic iomeprol is approved (Drugs@FDA, October 8, 2026).
- 2024 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the iomeprol label say about other medicines?
The iomeprol label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Metformin | drug interactions | Metformin can cause lactic acidosis in patients with renal impairment. |
Source: FDA drug label (IOMERVU), BRACCO DIAGNOSTICS INC, effective February 5, 2026 (SPL set cb2e0e00-7c93-0fb4-89a5-861641662a5a), via openFDA; the full label on DailyMed
What do FAERS reports show for iomeprol?
The FDA Adverse Event Reporting System holds 1,328 reports that list iomeprol among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 115 are coded as a death and 823 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radiographic contrast agents
- the pharmacologic class, with prices and generics
- Iomeprol side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other